Company intelligence / Profile preview

Ring Therapeutics

Cambridge, Massachusetts, United Statesringtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Ring Therapeutics has not yet reported clinical results. The company has presented promising preclinical data on its AnelloBricks biomanufacturing platform and continues to develop a portfolio of gene therapies using its proprietary anellovirus-based vectors.

Therapeutic areas: Metabolic DisordersOncologyRare DiseasesImmunologyHematologyOphthalmologyNeurology
Modalities: Gene therapyNucleic acid medicineViral vector-based therapy
Industry: Biotech

Drug pipeline

1 asset

AnelloVector

Preclinical

Partnerships

No major pharmaceutical partnerships publicly announced as of June 2025.

Beyond the preview

Go deeper on Ring Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ring Therapeutics.

Explore the full profile